ScoreWhy is Shanghai Serum Bio-Technology Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 16.43%
- The company has been able to generate a Return on Capital Employed (avg) of 16.43% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 1.90% and Operating profit at -2.66% over the last 5 years
3
Flat results in Mar 25
- NET PROFIT(HY) At CNY -15.51 MM has Grown at -29.97%
- DEBT-EQUITY RATIO (HY) Highest at -72.4 %
4
With ROE of 3.97%, it has a fair valuation with a 0.92 Price to Book Value
- Over the past year, while the stock has generated a return of 2.01%, its profits have risen by 0.8%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 2.01% in the last 1 year, much lower than market (China Shanghai Composite) returns of 12.36%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Shanghai Serum Bio-Technology Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Shanghai Serum Bio-Technology Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanghai Serum Bio-Technology Co., Ltd.
1.91%
2.10
38.40%
China Shanghai Composite
12.36%
0.86
14.45%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.90%
EBIT Growth (5y)
-2.66%
EBIT to Interest (avg)
40.36
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.17
Tax Ratio
10.03%
Dividend Payout Ratio
78.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.43%
ROE (avg)
4.24%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
0.92
EV to EBIT
5.62
EV to EBITDA
3.95
EV to Capital Employed
0.73
EV to Sales
1.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.06%
ROE (Latest)
3.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
PRE-TAX PROFIT(Q)
At CNY 3.17 MM has Grown at 389.44%
NET PROFIT(Q)
At CNY 2.85 MM has Grown at 746.38%
RAW MATERIAL COST(Y)
Fallen by -15.45% (YoY
-4What is not working for the Company
NET PROFIT(HY)
At CNY -15.51 MM has Grown at -29.97%
DEBT-EQUITY RATIO
(HY)
Highest at -72.4 %
Here's what is working for Shanghai Serum Bio-Technology Co., Ltd.
Pre-Tax Profit
At CNY 3.17 MM has Grown at 389.44%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 2.85 MM has Grown at 746.38%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Raw Material Cost
Fallen by -15.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanghai Serum Bio-Technology Co., Ltd.
Debt-Equity Ratio
Highest at -72.4 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
